Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 424 (OTC: $CSUI) (NASDAQ: $GWPH) (CSE: $PRMO.C) (TSX: $ZENA.TO)
Delta, Kelowna, BC, June 5, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/060520-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/06051CSUI-GWPH-PRMO-ZENA.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s
podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI), a research &
development company licensed under Swiss Cannabis and tobacco regulations to
cultivate and sell cannabis. The Company's facilities for producing cannabis
are based in Zurich.
The
Company grows high quality, organic cannabis with sustainable, all-natural
principles. Cannabis Suisse products are laboratory tested to ensure the end
users have access to a standardized, safe and consistent product.
In
today’s podcast we will be looking at a few public company announcements.
GW Pharmaceuticals
plc (NASDAQ:
GWPH), a world leader in the science, development, and
commercialization of cannabinoid prescription medicines, today
announced that the Company will host a virtual event for
investors to provide a review of the U.S. development program and market
opportunity for its late stage pipeline product, nabiximols. The program will
be webcast live on June 30, 2020 from 10:00 am-12:00 pm EDT, and a replay will
be available soon after the live presentation. Both the live webcast link and
the archive will be available on GW’s corporate website at www.gwpharm.com in the
Investor section under
Justin
Gover, GW’s Chief Executive Officer, will host this event. The presentation
will feature external medical and research experts as well as GW executives.
Nabiximols
is expected to enter pivotal Phase 3 development in the United States in the
second half of 2020. The U.S. commercial rights are owned by GW. GW anticipates
developing multiple indications for nabiximols with an initial focus on
spasticity. The initial target indication in the U.S. will be for the treatment
of MS spasticity, potentially to be followed by Spinal Cord Injury spasticity
and Post Traumatic Stress Disorder, or PTSD.
Nabiximols
is a complex botanical medicine formulated from extracts of the cannabis plant
that contains the principal cannabinoids THC and CBD and also contains minor
constituents, including other cannabinoid and non-cannabinoid plant components,
such as terpenes, sterols, and triglycerides. The product is administered as a
mouth spray.
Nabiximols
is known as Sativex® outside of the United States and is licensed and
commercially available for the treatment of MS spasticity in numerous
countries. The efficacy of Sativex for MS spasticity has been demonstrated in
multiple positive pivotal trials conducted in Europe.
PRIMO
NUTRACEUTICALS INC. (CSE:
PRMO) (OTC:
BUGVF) announced that further to its letter of intent with World Agri-Minerals Ltd. (“WAM”), announced in the
Company’s news release dated June 4, 2020, Primo and WAM have conducted
discussions relating to the development and production of a proprietary mineral
blend specially designed for employment by psilocybin mushroom growers.
The
Company has identified growing global interest in the potential medical
applications of psilocybin and other psychedelic mushrooms. With world-wide
interest in this burgeoning Agri-landscape, WAM is currently developing a new
proprietary mineral blend focused on enhancing the production and quality of
mushrooms and in particular psychedelic mushroom production. WAM claims that
their current research and testing will result in benefits similar to those
attained when using their already successful GENESIS 89 GOLD blend on Hemp and Cannabis production. With the new
WAM proprietary mineral natural mushroom blend, a healthy more vibrant and 100%
organic product can be grown more economically thereby allowing product cost
savings for the consumers in addition to enabling growers to be more efficient
and profitable. WAM claims that that GENESIS
89 GOLD can increase Hemp and Cannabis productivity anywhere from 15% to
35%. WAM believes that a new mushroom blend could provide similar if not
greater production numbers for psilocybin and other mushroom varieties grown
for medical applications.
According
to the Psychedelic Science Review, the global market for conventional
anti-depressants was valued at $13.7 billion in 2016 and is projected to grow
to $15.9 billion by 2023.
Andy
Jagpal, President of Primo Nutraceuticals commented, “We believe that Primo is
especially well positioned to capitalize on the emerging 'shroom boom'
Psilobycin and other varieties of mushrooms are quickly becoming a viable
option for mental and physical health treatment. The market for investment
opportunity is massive for a nutraceutical company like Primo which has
demonstrated its ability to receive NPNs (Natural Product Number) from the
Health Products and Food Branch of Health Canada for nutraceutical products.”
Zenabis Global Inc.
(TSX:
ZENA) announced that it
has assigned its binding term sheet with Farmako GmbH to its subsidiary company
ZenPharm for the supply of European
Union Good Manufacturing Practices certified medicinal cannabis and amended the
terms to provide for a minimum volume guarantee. The Company is also pleased to announce the
receipt of its sales license amendment for Zenabis Stellarton from Health
Canada.
●
Zenabis has assigned its term sheet with
Farmako, which was announced on April 29, 2019, to its Maltese-based European
joint venture, ZenPharm.
●
ZenPharm is expected to process EU GMP
compliant bulk from Zenabis to supply Farmako with a minimum of 500 kg per year
for a term of three years.
●
This is subject to ZenPharm itself
obtaining EU GMP certification, which is expected to occur in Q3, 2020.
●
Shipments to Farmako are expected to
commence in Q4, 2020.
●
ZenPharm anticipates supplying cannabis
oils to Farmako beginning in 2021.
Kevin
Coft, Chief Executive Officer of Zenabis, stated, "The assignment of this
term sheet, and addition of minimum volumes, reinforces Zenabis' impetus for
its international medicinal cannabis activities, in particular in Europe.
Working with key distributors like Farmako is vital in ensuring patient
accessibility to medicinal cannabis products in a manner that safeguards
quality and consistency of supply. Zenabis anticipates significantly increasing
supply to Europe from Q4 2020 onward, where bulk pricing of cannabis is now
significantly more attractive than in the Canadian market."
Katrin
Eckmans, Farmako Chief Executive Officer, stated, "Having visited Zenabis'
Canadian facility at the end of 2019, I was very impressed. We have visited many facilities, and Zenabis'
ability to maintain the highest standards of professionalism and quality
throughout the organization even while operating on a massive scale is
commendable. Zenabis' professional
approach to growing cannabis, combined with Natrix Sciences' experience with
innovative and complex pharmaceutical products in Malta is a perfect interplay
to provide a broad portfolio of high quality medical cannabis products for
patients in Germany and across Europe."
Angèle
Azzopardi, Chief Executive Officer ZenPharm said, "Our Team is incredibly
proud to carry this operation forward. This agreement not only showcases
Zenabis' commitment but also evidences the Zenabis, ZenPharm trans-Atlantic
synergy in delivering medicinal cannabis products to Europe. We look forward to
developing our relationship with Farmako, especially as more conventional
dosage forms of medicinal cannabis products come to the market."
Hightimes Holding
Corp.,
the owner of High Times®, the most well-known brand in cannabis,
today announces that it has entered into a series of agreements with Red, White & Bloom, Inc. with the
goal of the branding of High Times dispensaries and development of cannabis
based CBD and THC products in the States of Michigan, Illinois and Florida.
RWB
and its investee will use the Hightimes™ trademark,
logo and brand to rebrand its 18 planned and operational dispensaries as High
Times stores. Together, such stores represent more than 20% of the cannabis
market share across the state. RWB’S Investee is the leading cannabis company
in Michigan, with dispensaries, indoor/outdoor cultivation and product
manufacturing established over the last two years. In addition, as a result of
the acquisition of Newco, RWB will also acquire the rights to brand retail and
medical dispensaries and products, in the states of Illinois and Florida, and
may utilize RWB’s massive 3.6 million square foot facility in Illinois for the
production of proprietary branded CBD products and whole hemp flower strains
for distribution nationally.
In
addition to transforming the dispensaries to become High Times branded
destinations and launching delivery capabilities in select locations, High
Times branded products including vapes, tinctures, topicals, and edibles will
be available within both owned dispensaries and other 3rd party
outlets. The company has aggressive growth plans and is entering the market at
a time when the retail landscape has been significantly changed.
“High
Times is a 46-year-old brand with an immense amount of recognition and
credibility across the world,” said Peter Horvath, Chief Executive Officer of
Hightimes Holding Corp. “Licensing the High Times name, advising on dispensary
operations, and providing input on product development allows the company to
drive significant revenue from licensing fees without assuming the complexity
associated with owning and operating dispensaries and scaled cultivation and
manufacturing facilities nationwide. RWB has built an incredible and expansive
retail footprint in a quick time frame that we can strengthen through applying
the High Times Brand.”
The
Hightimes subsidiary holding the Hightimes™ trademark,
logo and brand worldwide, sublicensed such intellectual property to a newly
formed special purpose Hightimes subsidiary for the purpose of using and
branding retail and medical dispensaries and products in the State of Michigan
and, subject certain regulatory approvals, in the States of Illinois and
Florida as well. Under the terms of the agreement, the Hightimes Licensing
Company sold to RWB 100% of the equity of Newco. In consideration for the sale,
the Hightimes Licensing Company will receive $15,000,000 of RWB common shares
which are expected to trade on the Canadian Securities Exchange and, subject to
certain conditions, may receive an additional $5,000,000 of RWB common shares
in the future. In addition to the share consideration, the Hightimes Licensing
Company expects certain Minimum Guarantee payments during the term of the
agreement and any renewal period.
Hightimes
Holding Corp. has recently made several announcements ahead of the closing of
its Regulation A+ IPO, including the appointment of CEO Peter Horvath and its
proposed entry into retail cannabis dispensaries with the planned acquisition
of 13 California dispensaries from Harvest Health & Recreation, one of the
largest multi-state operators in cannabis. Through these and other strategic
transactions, High Times intends to become one of the largest cannabis
companies in California, and is working quickly to do the same in Michigan,
Illinois and Florida.
Once
again, today’s podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI), a
research & development company licensed under Swiss Cannabis and tobacco
regulations to cultivate and sell cannabis. The Company's facilities for
producing cannabis are based in Zurich.
The
Company grows high quality, organic cannabis with sustainable, all-natural
principles. Cannabis Suisse products are laboratory tested to ensure the end
users have access to a standardized, safe and consistent product.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com
website and this podcast is not an
ucts
or services or securities. Investors are reminded all investment involves risk
and possible loss of investment
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure CSUI is a paid monthly news and social media
cannabis stock More disclaimer
info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
